University Health Network

Xor-labs Toronto Inc.

Mingyao Liu

Marcelo Cypel

Shaf Keshavjee

Thomas Kenneth Waddell

Lahav Gil

Shafique Keshavjee

Martin Leandro Par

Geoffrey Samuel Frost

Philipp Stücklin

David Christopher Lynch

Grzegorz Piotr Burdyszek

Siew Hong Tan

An organ perfusion device includes an inlet for connection to the organ, and an outlet for connection to the organ. The device also includes a perfusion circuit including: a reservoir configured to hold a perfusion fluid; a waste receptacle, and a plurality of fluid conduits. The fluid conduits define: a delivery fluid path connecting the reservoir with the inlet; a return fluid path, independent of the delivery fluid path, connecting the reservoir with the outlet; and a waste fluid path connecting the reservoir with the waste receptacle. The device also includes a first flow control device configured to selectively prevent or allow fluid flow from the reservoir to the organ via the delivery fluid path; and a second flow control device configured to selectively prevent or allow fluid flow from the reservoir to the waste receptacle via the waste fluid path.

Organ perfusion device and method

Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.

Methods for determining risk of chronic lung allograft dysfunction (CLAD) and subtypes thereof

A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate for transplant.

Methods and compositions for assessing lung grafts

Methods and compositions for determining the suitability of a lung for transplantation are described.

Diagnostic assay for lung transplant

Growing community of inventors

North York, Canada

Mingyao Liu